

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

PROPOSED ADOPTION OF CHINESE NAME CHANGE OF DATE OF ANNUAL GENERAL MEETING AND BOOK CLOSURE PERIOD

Reference is made to the annual results announcement for the year ended December 31, 2023 of the Company dated March 28, 2024 (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

PROPOSED ADOPTION OF CHINESE NAME

The Board of Directors of the Company proposes to adopt the Chinese name “思路迪医药股份有限公司” as the dual foreign name of the Company (the “**Proposed Adoption of Chinese Name**”).

Conditions of the Proposed Adoption of Chinese Name

The Proposed Adoption of Chinese Name is subject to the following conditions:

- (1) the passing of a special resolution by the Shareholders at the forthcoming AGM of the Company approving the Proposed Adoption of Chinese Name; and
- (2) the Registrar of Companies of the Cayman Islands approving the Proposed Adoption of Chinese Name.

Subject to the satisfaction of the above conditions, the Proposed Adoption of Chinese Name will take effect from the date on which the Registrar of Companies in the Cayman Islands enters the new dual foreign name in Chinese of the Company on the register of companies maintained by the Registrar of Companies in the Cayman Islands. Thereafter, the Registrar of Companies in the Cayman Islands will issue a certificate of incorporation on adoption of dual foreign name. Upon the Proposed Adoption of Chinese Name becoming effective, the Company will comply with the necessary filing procedures in Hong Kong and the Cayman Islands.

Reasons for the Proposed Adoption of Chinese Name

The Board considers that the Proposed Adoption of Chinese Name is in line with the Group’s strategic and business development direction to further strengthen its presence in the Greater China market and to enhance its corporate image and identity. Accordingly, the Board considers that the Proposed Adoption of Chinese Name will benefit the Group’s future business development and is in the best interests of the Company and its Shareholders as a whole.

Effect of the Proposed Adoption of Chinese Name

The Proposed Adoption of Chinese Name will not, of itself, affect the rights of any shareholder of the Company or the Company's daily business operation and its financial position. All existing share certificates of the Company bearing the existing names of the Company will, after the Proposed Adoption of Chinese Name becomes effective, continue to be evidence of legal title to the shares of the Company and valid for trading, settlement, registration and delivery purposes. Accordingly, there will not be any arrangements for free exchange of existing share certificates for new share certificates bearing the existing English name and the dual foreign name in Chinese of the Company. Share certificates of the Company which are issued after the Proposed Adoption of Chinese Name becomes effective will be in the new name of the Company. Subject to the confirmation by the Stock Exchange, the Shares will be traded on the Stock Exchange in the new stock short name of the Company after the Proposed Adoption of Chinese Name becomes effective.

Accordingly, there will not be any arrangement for the free exchange of the existing share certificates for new share certificates bearing both the English name and dual foreign name of the Company. Should the Proposed Adoption of Chinese Name become effective, any issue of new share certificates thereafter will bear both the English and the dual foreign name of the Company. The stock code of the Company will remain unchanged as "1244". The Shares will be traded on the Stock Exchange under the existing English stock short name. Subject to confirmation by the Stock Exchange, upon the Proposed Adoption of Chinese Name becoming effective, the Chinese stock short name for trading of Shares on the Stock Exchange will be changed.

Further announcement(s) will be made by the Company to inform the Shareholders of the effective date of the Proposed Adoption of Chinese Name as and when appropriate.

CHANGE OF DATE OF ANNUAL GENERAL MEETING AND BOOK CLOSURE PERIOD

As set out in the Announcement, the forthcoming AGM was initially scheduled to be held on Wednesday, June 26, 2024, and for the purpose of determining the identity of the Shareholders who are entitled to attend the AGM, the register of members of the Company was initially scheduled to be closed from Friday, June 21, 2024 to Wednesday, June 26, 2024 (both days inclusive).

The Company hereby announces that the date of the AGM will be rescheduled to Friday, June 28, 2024 due to administrative reason. As such, the register of members of the Company will be closed from Tuesday, June 25, 2024 to Friday, June 28, 2024, both days inclusive, in order to determine the identity of the Shareholders who are entitled to attend the AGM, during which period no share transfers will be registered.

To be eligible to attend the AGM, all properly completed transfer forms accompanied by the relevant share certificates must be lodged for registration with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Monday, June 24, 2024.

For details of the time and venue of the AGM, the resolutions to be considered and other related matters, please refer to the notice and circular in relation to the AGM to be despatched by the Company in due course.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong
June 3, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.